Latiglutenase
- Generic Name
- Latiglutenase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1360452-96-5
- Unique Ingredient Identifier
- 090PL12YZJ
- Indication
Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Latiglutenase in T1D/CD Patients
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04839575
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 83
- Registration Number
- NCT04243551
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Latiglutenase as a Treatment for Celiac Disease
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Immunogenics, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT03585478
- Locations
- 🇺🇸
Mayo Clinic - 200 First Street SW, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath